Daily Bulletin

Men's Weekly

.

Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT05249127[1]) for patients with prostate...

Read more: Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

Business News

Integrating Marketing Automation Workflows with Headless CMS: Creating a Unified Engine for Scalable Growth

Marketing automation is a necessary component of modern engagement with customers. Automated emails, triggered campaigns, lead nurturing and lifecycle messaging enable brands to scale their messagin...

Daily Bulletin - avatar Daily Bulletin

Why Split Corrugated Conduits Are Essential For Protecting Electrical And Solar Installations

Modern electrical systems require reliable protection for wiring and cables to ensure safety, durability, and long-term performance. In residential, commercial, and industrial environments, conduits a...

Daily Bulletin - avatar Daily Bulletin

Launching Global Product Campaigns with Decoupled Content Architecture

There's perhaps no more challenging project for an international enterprise to pursue than a global product launch campaign. At the same time, various regions, languages, compliance standards, digit...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business